Abstract: Provided are engineered cells containing one or more modifications, such as genetic modifications, for use in cardiac cell therapies. In some embodiments, the one or more modifications attenuate or prevent engraftment arrhythmia associated with a cardiac cell therapy.

Abstract: Provided herein are methods of producing lipid membrane bound particles, such as lentiviral vectors, that contain one or more Paramyxovirus envelope proteins in the lipid bilayer. Also provided are lipid membrane bound particles containing one or more Paramyxovirus envelope proteins in the lipid bilayer. In some embodiments, the one or more Paramyxovirus envelope protein is a Nipah virus (NiV) protein G or F or a biologically active portion or retargeted fusion thereof. In some embodiments, the lipid membrane bound particle is a lentiviral vector. Also provided are related compositions, kits and systems in connection with the provided methods.

Abstract: Provided herein are lipid particles, such as lentiviral particles, that incorporate or are pseudotyped with a variant Nipah Virus F (NiV-F) envelope glycoprotein, and in some aspects also an attachment glycoprotein (G) protein such as a NiV-G protein or a biologically active portion or variant thereof. Also provided are polynucleotides encoding the variant NiV-F and producer cells for preparation of the lipid particles, such as lentiviral particles, containing the variant NiV-F proteins, as well as methods for preparing and using the lipid particles, such as lentiviral particles.

Abstract: Provided are engineered cells containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy. In some embodiments, the engineered cells are hypoimmunogenic cells. In some embodiments, the engineered cells comprise increased expression of CD46 and CD59.

Abstract: Provided herein are lipid particles, such as lenti viral particles, that incorporate or are pseudotyped with a variant Nipah Virus G (NiV-G) envelope glycoprotein, and in some aspects also a fusion (F) protein such as a NiV-F protein or a biologically active portion or variant thereof. Also provided are polynucleotides encoding the variant NiV-G and producer cells for preparation of the lipid particles, such as lentiviral particles, containing the variant NiV-G proteins, as well as methods for preparing and using the lipid particles, such as lentiviral particles.

Abstract: Provided are engineered cells containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy. In some embodiments, the engineered cells are hypoimmunogenic cells.

Abstract: Provided herein are methods of transducing resting or non-activated T cells using CD4-targeted viral vectors.

Abstract: Provided herein are lipid particles, such as lentiviral particles, that incorporate or are pseudotyped with a truncated Baboon Endogenous Retrovirus (BaEV) envelope glycoprotein that contains a cytoplasmic tail with a partial inhibitory R peptide that is less than the full length wildtype BaEV inhibitory R peptide. Also provided herein are polynucleotides encoding the truncated BaEV envelope glycoproteins and producer cells for preparation of the lipid particles, such as lentiviral particles, containing the truncated BaEV envelope glycoproteins, as well as methods for preparing and using the lipid particles, such as lentiviral particles.

Abstract: Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation. Provided herein are engineered and/or hypoimmunogenic cells exhibiting reduced expression of MHC class I and/or MHC class II human leukocyte antigens and T-cell receptors. In some embodiments, such cells also exogenously express one or more tolerogenic factors such as CD47 and one or more chimeric antigen receptors (CAR)s.

Abstract: Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation. Provided herein are engineered and/or hypoimmunogenic cells exhibiting reduced expression of MHC class I and/or MHC class II human leukocyte antigens and T-cell receptors. In some embodiments, such cells also exogenously express one or more tolerogenic factors such as CD47 and one or more chimeric antigen receptors (CAR)s.

Abstract: Provided are engineered cells, such as engineered primary cells, containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy. In some embodiments, the engineered primary cells are hypoimmunogenic cells.

Abstract: Disclosed herein are engineered cells and/or hypoimmunogenic cells including engineered and/or hypoimmunogenic stem cells, engineered and/or hypoimmunogenic cells differentiated therefrom, engineered and/or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and/or hypoimmunogenic stem cells) and related methods of their use and generation. Provided herein are engineered and/or hypoimmunogenic cells exhibiting reduced expression of MHC class I and/or MHC class II human leukocyte antigens and T-cell receptors. In some embodiments, such cells also exogenously express one or more tolerogenic factors such as CD47 and one or more chimeric antigen receptors (CAR)s.

Abstract: Provided herein are methods of treating a virus infection, such as a coronavirus infection, by delivering to a subject in need a binding agent, wherein the binding agent comprising (i) at least one binding domain that binds to a viral protein expressed on the surface of a virus, and (ii) a modified Fc domain that exhibits either (a) reduced binding to an Fc activating receptor or (b) increased binding to an Fc inhibitory receptor compared to a wild-type Fc domain. The binding agent may be delivered as a polynucleotide (e.g. mRNA) or as a protein, and may be contained in a vehicle for delivery, such as a viral or non-viral vector. The present disclosure also relates to the polynucleotides, proteins, and vehicles (e.g. viral and non-viral vector) and composition thereof, including for use in the methods.

Abstract: Provided herein are methods of treating or reducing the likelihood of a virus infection, such as a coronavirus infection, by delivering to a subject in need a Chromosome 19 Open Reading Frame 66 (C19orf66) or a regulatory factor that increases expression of the gene encoding C19ord66 in a cell in a subject. The C19orf66 or regulatory factor may be delivered as a polynucleotide (e.g. mRNA or DNA) or as a protein, and may be contained in a vehicle for delivery, such as a viral or non-viral vector. Also provided are polynucleotides, proteins, and vehicles (e.g. viral and non-viral vector) and composition thereof, including for use in the methods.

Abstract: Disclosed herein are antibodies or antigen binding fragments thereof that specifically bind human CD8. Also disclosed are fusion proteins comprising a Henipavirus glycoprotein G and CD8 antibodies for targeting and transducing cells expressing CD8. Viral vectors and other compositions containing the fusion proteins, as well as methods of using the fusion proteins, are also disclosed.

Abstract: Provided are methods and uses related to cardiomyocyte cell therapies involving the administration of immunosuppressive agents for reducing or preventing rejection of administered allogeneic cardiomyocytes. In some embodiments, the methods are for treating a subject with a heart disease or condition in combination with a cardiomyocyte cell therapy.

Abstract: Provided herein are methods of transducing resting or non-activated T cells using CD8-targeted viral vectors.

Abstract: Provided herein are lipid particles containing a lipid bilayer enclosing a lumen or cavity, a henipavirus F protein molecule or biologically active portion thereof, and a targeted envelope protein containing a henipavirus envelope attachment glycoprotein G (G protein) or biologically active portion thereof and a binding domain, such as a single domain antibody (sdAb) variable domain. Also provided herein are targeted envelope proteins containing a G protein fused or linked to a binding domain, such as a sdAb variable domain, and polynucleotides encoding such proteins. Also provided are producer cells and compositions containing such targeted lipid particles and methods of making and using the targeted lipid particles.